Patents
Literature
38 results about "Steatonecrosis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Implants and methods for treating bone
ActiveUS20060089715A1Eliminate needInternal osteosythesisSpinal implantsVertebra compression fractureBiodegradable magnesium
An orthopedic implant comprising a deformable, expandable implant body configured for treating abnormalities in bones, such as compression fractures of vertebra, necrosis of femurs and the like. An exemplary implant body comprises a small cross-section threaded element that is introduced into a bone region and thereafter is expanded into a larger cross-section, monolithic assembly to provide a bone support. In one embodiment, the implant body is at least partly fabricated of a magnesium alloy that is biodegradable to allow for later tissue ingrowth.
Owner:DFINE INC
Regulation of transforming growth factor-beta (TGF-beta) gene expression in living cells via the application of specific and selective electric and electromagnetic fields
InactiveUS7465546B2ElectrotherapyMicrobiological testing/measurementElectromagnetic fieldTarget tissue
Methods and devices are described for the regulation of Transforming Growth actor (TGF)-β1, β2, and / or β3 protein gene expression in bone cells and other tissues via the capacitive coupling or inductive coupling of specific and selective electric fields to the bone cells or other tissues, where the specific and selective electric fields are generated by application of specific and selective electric and electromagnetic signals to electrodes or one or more coils or other field generating device disposed with respect to the bone cells or other tissues so as to facilitate the treatment of diseased or injured bone and other tissues. By gene expression is meant the up-regulation or down-regulation of the process whereby specific portions (genes) of the human genome (DNA) are transcribed into mRNA and subsequently translated into protein. Methods and devices are provided for the targeted treatment of injured or diseased bone and other tissue that include generating specific and selective electric and electromagnetic signals that generate fields in the target tissue optimized for increase of TGF-β1, β2, and / or β3 protein gene expression and exposing bone and other tissue to the fields generated by specific and selective signals so as to regulate TGF-β1, β2, and / or β3 protein gene expression in such tissue. The resulting methods and devices are useful for the targeted treatment of bone fractures, fractures at risk, delayed unions, nonunion of fractures, bone defects, spine fusions, osteonecrosis or avascular necrosis, as an adjunct to other therapies in the treatment of one or all of the above, in the treatment of osteoporosis, and in other conditions in which TGF-β1, β2, and / or β3 protein may be implicated.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Regulation of transforming growth factor-beta (TGF-beta) gene expression in living cells via the application of specific and selective electric and electromagnetic fields
InactiveUS20060235473A1ElectrotherapyMicrobiological testing/measurementHuman DNA sequencingElectromagnetic field
Methods and devices are described for the regulation of Transforming Growth actor (TGF)-β1, β2, and / or β3 protein gene expression in bone cells and other tissues via the capacitive coupling or inductive coupling of specific and selective electric fields to the bone cells or other tissues, where the specific and selective electric fields are generated by application of specific and selective electric and electromagnetic signals to electrodes or one or more coils or other field generating device disposed with respect to the bone cells or other tissues so as to facilitate the treatment of diseased or injured bone and other tissues. By gene expression is meant the up-regulation or down-regulation of the process whereby specific portions (genes) of the human genome (DNA) are transcribed into mRNA and subsequently translated into protein. Methods and devices are provided for the targeted treatment of injured or diseased bone and other tissue that include generating specific and selective electric and electromagnetic signals that generate fields in the target tissue optimized for increase of TGF-β1, β2, and / or β3 protein gene expression and exposing bone and other tissue to the fields generated by specific and selective signals so as to regulate TGF-β1, β2, and / or β3 protein gene expression in such tissue. The resulting methods and devices are useful for the targeted treatment of bone fractures, fractures at risk, delayed unions, nonunion of fractures, bone defects, spine fusions, osteonecrosis or avascular necrosis, as an adjunct to other therapies in the treatment of one or all of the above, in the treatment of osteoporosis, and in other conditions in which TGF-β1, β2, and / or β3 protein may be implicated
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Steerable drill for minimally-invasive surgery
An embodiment in accordance with the present invention provides a continuum dexterous manipulator (CDM) with a specially designed flexible tool, to be used as a handheld or robotic steerable device for treatment of hard-tissue-related diseases. The CDM of the present invention works well in treatment of soft and sticky material (similar to a lesion) as well as milling the hard tissues (e.g. sclerotic liner of osteolytic lesions) and bone tumors. The present invention is also directed to flexible drilling tools as well as characterization and evaluation of integrating these tools with the CDM in curved-drilling of hard bone towards treatment of hard tissue related diseases (e.g. osteonecrosis or pelvic fracture). The present invention can also include use of various types of drill geometries, aspiration and irrigation, and endoscope view in curved-drilling and trajectory planning.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Strontium-Containing Compounds for Use in the Prevention or Treatment of Necrotic Bone Conditions
InactiveUS20080167513A1Heavy metal active ingredientsSkeletal disorderLegg-Calve-Perthes diseaseGlucocorticoid
A method for the treatment and / or prophylaxis of an ostenonecrotic bone disease in a mammal in need thereof, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia / osteonecrosis, Legg-Calve-Perthes disease and femoral head necrosis, the method comprising administering an effective dose of a strontium-containing compound (a) to the mammal. A method for the treatment and / or prophylaxis of an osteonecrotic bone disease, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia / osteonecrosis and femoral head necrosis, in a mammal who is to be or is treated with a therapeutic agent (b) known to or suspected of inducing apoptosis and / or necrosis of bone cells, the method comprising administering a strontium-containing compound (a) in combination with (b).
Owner:OSTEOLOGIX AS
Medicine for treating osteoporosis and its preparing method and use
ActiveCN1781535ASignificant effectGood curative effectSkeletal disorderSolution deliverySide effectEpimedium
The patent application relates to a kind of osteoporosis treating medicine and its preparation process as well as its new use in treating fracture, osteoarthritis, osteonecrosis and climacteric syndrome. The medicine is prepared with epimedium, teasel root, red sage, anemarrhena rhizome, malaytea scurfpea fruit and rehmannia root. Clinical and animal experiment research shows that the medicine has higher curative effect and no side effect compared with other medicine for treating osteoporosis, and may be taken regularly.
Owner:GUOYAOJITUAN TONGJITANG (GUIZHOU) PHARMA CO LTD
Methods and Pharmaceutical Compositions for the Treatment of Bone Density Related Diseases
InactiveUS20130195863A1Decreased bone mineral densityIncreasing bone mineral densityOrganic active ingredientsPeptide/protein ingredientsGhosal hematodiaphyseal dysplasiaBone density
The invention relates to methods and pharmaceutical compositions for the treatment of bone density related diseases. More particularly, the present invention relates to a ROBO1 modulator for use in a method for the treatment of a bone mineral density related disease in a subject. In a particular embodiment the ROBO1 modulator is selected from the group consisting of small organic molecules, antibodies, aptamers or polypeptides. In another particular embodiment said bone mineral density related disease is selected from the group consisting of ghosal hematodiaphyseal dysplasia syndrome (GHDD), osteoporosis, osteoporosis associated to pseudoglioma, osteoporosis and oculocutaneous hypopigmentation syndrome, osteoporosis due to endocrinological dysfunction, osteogenesis imperfecta osteopenia, Paget's disease, osteomyelitis, hypercalcemia, osteonecrosis, hyperparathyroidism, lytic bone metastases, periodontitis, bone loss due to immobilization and osteoporosis associated with a disease selected from the group consisting of cachexia, anorexia, alopecia, rheumatoid arthritis, psoriatic arthritis, psoriasis, and inflammatory bowel disease.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Regulation of fibroblastic growth factor-2 (FGF-2) gene expression in living cells with the application of specific and selective electric and electromagnetic fields
InactiveUS7981611B2ElectrotherapyMicrobiological testing/measurementHuman DNA sequencingElectromagnetic field
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Medicine for preventing medicine-related osteonecrosis of jaw
The invention discloses a medicine for preventing medicine-related osteonecrosis of the jaw. The medicine uses a DNA tetrahedron as an effective ingredient. Experiments show that the DNA tetrahedron can reverse the inhibitory effect of zoledronic acid, dexamethasone and other medicines on osteoclast, and can relatively well prevent medicine-related osteonecrosis of the jaw.
Owner:SICHUAN UNIV
Medicine for treating ischemic necrosis of head of femur and preparation method thereof
InactiveCN1404863APromote blood circulationReduce necrosisSkeletal disorderUnknown materialsIschemic necrosisFemur
The composition of the Chinese medicine with the functions of effectively improving blood circulation of bone, raising volume of blood flow, reducing internal pressure of bone, inhibiting platelet aggregation, reducing osteonecrosis and promoting osteonecrosis regeneration for curing ischemic necrosis of femoral head is formed from 12 Chinese medicinal materials of notoginseng, ligusticum root, cordydalis tuber, Chinese angelica root, saussurea root, millettia root and stem and others.
Owner:郭永昌
Deferoxamine derivative compound with bone affinity, preparation method and application thereof
The invention develops a deferoxamine derivative with bone affinity, a preparation method and application thereof. More specifically, the invention provides a compound with a structure shown as formula (1) and its pharmaceutically acceptable salt, ester, amide, acyl halide, hydrate or solvate. The invention also provides a preparation method of the compound shown as formula (1) and application thereof in preparation of drugs for treatment of osteoporosis, osteonecrosis, delayed union or nonunion and bone defect. (formula I).
Owner:上海市伤骨科研究所
Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
A method for the treatment and / or prophylaxis of an osteonecrotic bone disease in a mammal in need thereof, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia / osteonecrosis, Legg-Calve-Perthes disease and femoral head necrosis, the method comprising administering an effective dose of a strontium-containing compound (a) to the mammal. A method for the treatment and / or prophylaxis of an osteonecrotic bone disease, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia / osteonecrosis and femoral head necrosis, in a mammal who is to be or is treated with a therapeutic agent (b) known to or suspected of inducing apoptosis and / or necrosis of bone cells, the method comprising administering a strontium-containing compound (a) in combination with (b).
Owner:OSTEOLOGIX AS
System and method for the ultrasonic treatment of fractures, bone, muscle and tendon injuries, post-surgery pain and osteonecrosis in human and veterinary medicine, and uses thereof
ActiveUS11389672B2Minimize the possibilityIndependent controlUltrasound therapyMechanical/radiation/invasive therapiesThoracic boneWeb service
The invention consists of an electronic system for controlled and independent treatment of fractures, bone, muscle and tendon injuries, post-surgery pain and osteonecrosis, composed by a portable ultrasound generator, electronic prescription, centralised web services platform and computer program for ultrasonic treatment both within and outside the sanitary field, in the fields of human and veterinary medicine. The method controls the treatment applied, the charge prescribed by healthcare professionals by means of an electronic prescription, which can be administered by the patients themselves or by non-healthcare professionals independently, under the control of a computer program and a web platform used to activate the therapeutic equipment, write and delete the electronic prescription, transfer data stored in the therapeutic equipment to the web services platform to analyse the quantity and quality of the treatments, and update the program. Portable generator of ultrasonic pulses with set, unalterable parameters for the treatment of thorax, rib and sternum fractures, and of pain after thoracic surgery.
Owner:NORCRI INVEST SL
Micropowder medicament for treating bone fractures and preparation method thereof
InactiveCN101961446AGrow fastGood effectHeavy metal active ingredientsPowder deliveryPyrolusiteMyrrh
The invention relates to a micropowder medicament for treating bone fractures such as fracture, paralysis, osteonecrosis and bone fracture sequelae which are caused by trauma and the like and a preparation method thereof. The micropowder medicament comprises the following raw material medicaments: 4 to 7 parts of pyrite, 2 to 5 parts of herry rhodiola, 2 to 5 parts of frankincense, 2 to 5 parts of myrrh, 1 to 5 parts of safflower, 1 to 4 parts of garden balsam stem, 3 to 5 parts of prepared rhubarb, 2 to 5 parts of dioscorea nipponica, 3 to 6 parts of sea cucumber, 1 to 2 parts of gecko tail, 3 to 7 parts of pyrolusite and the like. The preparation method comprises the step of grinding the raw material medicaments into fine powder with the grain diameter of 300 to 1,000 meshes by a low-temperature freeze drying method, and preparing capsules for oral administration, or blending on site to form paste for external application; moreover, the medicament can be used for oral administration and external application simultaneously. The micropowder medicament has the excellent effect on closed fracture except for head injury, and particularly for traumatic patients who suffer from the bone fractures, both the trauma and the bone fractures can be treated. By the invention, more patients who suffer from the bone fractures and particularly serious patients do not suffer from amputation, do not need wheelchairs, and are recovered quickly, without sequela.
Owner:张智富 +1
Customized load-bearing and bioactive functionally-graded implant for treatment of osteonecrosis
An engineered medical device for treatment of osteonecrosis is provided where the size, porosity and ceramic content of the device can be personalized based on an individual patient's anatomical and physiological condition. The device distinguishes different segments mimicking anatomically-relevant cortical and cancellous segments, in which the cortical segments of the device can sustain mechanical loading, and the cancellous segment of the device can promote bone ingrowth, osteogenesis and angiogenesis.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Methods of treating osteonecrosis with llp2a-bisphosphonate compounds
PendingUS20210205338A1Avoid cell deathReduce the amount requiredOrganic active ingredientsAnthropod material medical ingredientsDiphosphonatesMesenchymal stem cell
Methods of treating osteonecrosis in a subject are provided. In some embodiments, the method comprises administering to a subject having or suspected of having osteonecrosis a pharmaceutical composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug. In some embodiments, the pharmaceutical composition comprises a conjugate of LLP2A and alendronate (LLP2A-Ale). In some embodiments, the method further comprises administering exogenous mesenchymal stem cells.
Owner:RGT UNIV OF CALIFORNIA
Mesenchymal stromal cell bone graft material
PendingUS20220305058A1Reduce lossesInduce denaturationUnknown materialsTissue regenerationCells boneStromal cell
The invention pertains to the use of mesenchymal stromal cells (MSC) in the treatment of bone disorders or injuries. The invention provides MSC and preparations of specifically pooled MSC for use in the manufacturing of bone graft material for implanting into or attaching to bones in order to enhance bone regeneration after surgery or injury, or to treat various bone disorders, such as osteonecrosis. The invention provides bone graft material, a method for its production, bone graft implants, and medical methods and uses of the inventive products.
Owner:JOHANN WOLFGANG GOETHE UNIV FRANKFURT AM MAIN
Traditional Chinese medicine for treating bone fracture and osteonecrosis and preparation method thereof
PendingCN114796416APromote synthesis and secretionElicit activitySkeletal disorderFungi medical ingredientsMyrrhUltraviolet lights
The invention particularly relates to a traditional Chinese medicine for treating bone fracture and osteonecrosis and a preparation method thereof. The traditional Chinese medicine for treating bone fracture and osteonecrosis is prepared from the following components in parts by mass: 2 to 4 parts of tree hair, 6 to 8 parts of dragon's blood, 8 to 10 parts of frankincense, 8 to 10 parts of myrrh, 5 to 7 parts of sambucus chinensis, 4 to 6 parts of semen momordicae, 30 to 40 parts of semen vaccariae, 2 to 4 parts of saffron crocus, 1 to 2 parts of fructus amomi rotundus, 2 to 4 parts of acanthopanax seeds, 7 to 10 parts of synthetic bone setting pills and 8 to 14 parts of radix notoginseng. The preparation method of the traditional Chinese medicine for treating bone fracture and osteonecrosis comprises the following steps: repeatedly calcining the synthesized bone setting pill, quenching with concentrated vinegar, breaking the wall into particles, sieving with a 240-mesh sieve, mixing with various medicines, sterilizing for 3-5 hours under an ultraviolet lamp, and filling into capsules or tabletting. The traditional Chinese medicine is short in bone fracture disease treatment time, good in effect and free of adverse reactions and side effects.
Owner:田力
Use of metformin to mitigate corticosteroid-associated osteonecrosis or osteoporosis
Compositions and methods are provided for the prevention of osteonecrosis or osteoporosis associated with corticosteroid administration in an individual. The methods of the disclosure comprise administration of an effective dose of a metformin agent, or a derivative, mimetic or analog thereof in combination with administration of a corticosteroid. The effective dose of metformin agent decreases oxidative stress and restores osteogenic capacity of mesenchymal stem cells exposed to a glucocorticoid.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Drug for treating femoral head necrosis and promoting bone regeneration
InactiveCN105582275ARestoration of sports weight bearing functionPromote regenerationDispersion deliverySkeletal disorderGlucocorticoidSide effect
The invention relates to a drug for disease treatment, in particular to a drug for treating femoral head necrosis and promoting bone regeneration. The drug is prepared through decoction of multiple traditional Chinese medicines including radix dipsaci asperoidis, fructus psoraleae, rhizoma drynariae, williams elder twig and rhizoma chuanxiong. The toxic and side effects are small. The drug is suitable for patients suffering from femoral head necrosis caused by long-term using of glucocorticoid, and patients suffering from femoral head avascular necrosis caused by long-term drinking or trauma, and can promote revascularization and repair of the necrosis part so as to treat femoral head necrosis and recover the moving and weight bearing functions of the femoral head to the maximum. The drug is mainly clinically applied to patients suffering from femoral head necrosis and osteonecrosis caused by glucocorticoid.
Owner:姜桂芹
Early osteonecrosis diagnosis kit based on blood detection and biomarkers
The invention discloses an osteonecrosis early diagnosis kit based on blood detection and a biomarker, and the osteonecrosis early diagnosis kit can be used for early diagnosis of osteonecrosis through multi-omics screening based on femoral head necrosis lesion division, serological analysis of different stages of cases and cell and animal level biological tests in combination with actual detection result verification. It is determined that a group of biomolecules, namely PEBP1, ACAT1, MMP2, SOD1 and FN1 proteins, can be used for early diagnosis of osteonecrosis.
Owner:XI AN JIAOTONG UNIV
Methods of treating osteonecrosis with LLP2A-bisphosphonate compounds
ActiveUS12569506B2Organic active ingredientsAnthropod material medical ingredientsMesenchymal stem cellPharmaceutical drug
Methods of treating osteonecrosis in a subject are provided. In some embodiments, the method comprises administering to a subject having or suspected of having osteonecrosis a pharmaceutical composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug. In some embodiments, the pharmaceutical composition comprises a conjugate of LLP2A and alendronate (LLP2A-Ale). In some embodiments, the method further comprises administering exogenous mesenchymal stem cells.
Owner:RGT UNIV OF CALIFORNIA
Methods of treating osteonecrosis with LLP2A-bisphosphonate compounds
ActiveJP7805024B2Organic active ingredientsAnthropod material medical ingredientsSteatonecrosisOrganic chemistry
To provide methods of treating osteonecrosis in a subject.SOLUTION: In some embodiments, the method comprises administering to a subject having or suspected of having osteonecrosis a pharmaceutical composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug. In some embodiments, the pharmaceutical composition comprises a conjugate of LLP2A and alendronate (LLP2A-Ale). In some embodiments, the method further comprises administering exogenous mesenchymal stem cells.SELECTED DRAWING: Figure 2
Owner:RGT UNIV OF CALIFORNIA
Application of xylaria nigriper powder to preparation of medicines or healthcare food for preventing and treating osteoporosis and osteonecrosis
ActiveCN105998088ANormal microstructureNormal thicknessSkeletal disorderFood ingredient functionsBone densityRight femoral head
The invention discloses application of xylaria nigriper powder to preparation of medicines or healthcare food for preventing and treating osteoporosis and osteonecrosis. According to animal pharmacological experiments, the xylaria nigriper powder is capable of increasing bone mineral density and bone calcium and phosphorus content of osteoporosis model rats and increasing bone mass to make bone tissue microstructures tend to be normal; the xylaria nigriper powder is also capable of remarkably increasing femoral head capillary distribution of steroid-induced femoral head necrosis model rats and reducing fat deposition in femoral head bone tissues of the steroid-induced femoral head necrosis model rats; the xylaria nigriper powder is capable of remarkably increasing bone trabecula area fraction of alcoholic femoral head necrosis model rats and remarkably reducing empty lacuna count to realize normal morphology of bone cells in bone lacunae. According to clinical researches, the xylaria nigriper powder has a remarkable treatment effect on osteoporosis, steroid-induced femoral head necrosis and alcoholic femoral head necrosis. The xylaria nigriper powder is reliable in curative effect and high in safety and has a promising clinical application prospect.
Owner:雷允上药业集团有限公司
Bone recovering pill for treating bone necrosis
InactiveCN101628065BCompatibility is reasonableDrug symptoms matchSkeletal disorderUnknown materialsDiseaseSide effect
The invention belongs to the technical field of the traditional Chinese medicine, which in particular discloses a bone recovering pill for treating bone necrosis. The bone recovering pill is prepared from antler, radix clematidis, tortoise shell, twotooth achyranthes root, safflower, curculigo orchioides, prepared rehmannia root, radix notoginseng, angelica, radix morindae officinalis, astragalusroot, draconis sanguis, eucommia bark and rhizoma drynariae according to certain weight mixture ratio. The invention has the effects of induing menstruation to relieve menalgia, reinforcing the kidney to strengthen the bone, invigorating qi, tonifying the blood, promoting blood circulation and relieving the stasis of blood and has reasonable matching, coincidence of the medicine and the disease, positive curative effect and no side effect.
Owner:刘成玉
Medicinal composition for treating rheumatism and rheumatoid arthritis
InactiveCN101732579BHeavy metal active ingredientsAnthropod material medical ingredientsCervical spondylosisSciatica
The invention discloses a medicinal composition for treating rheumatism and rheumatoid arthritis. The medicinal composition consists of more than 20 medicaments, such as fortune's drynaria rhizome, processed nux vomica, scorpion, himalayan teasel root, frankincense, myrrh, diversifolious patrinia root and the like and has no side effect of chemical medicaments. The medicinal composition has the effects of drilling tendon, penetrating bone, activating tendons, expelling wind, relieving pain and eliminating stagnation and has the remarkable treatment effects of treating the rheumatism, the rheumatoid arthritis, scapulohumeral periarthritis, sciatica, gout, cervical spondylosis, herniated disk, hyperosteogeny, osteonecrosis and lupus erythematosus.
Owner:朱平东
Traditional Chinese medicine composition for treating rheumatism and bone disease and preparation method of composition
The invention discloses a traditional Chinese medicine composition for treating the rheumatism and bone disease. The traditional Chinese medicine composition is prepared from radix aconiti carmichaeli, frankincense, pseudo-ginseng, radix angelicae, radix aconiti, rhizoma drynariae, flos carthami, dried bodies of buthus martensii Karsch, rhizoma atractylodis, honey, radix puerariae, zaocys dhumnades, rhizoma sinomeni cauliset, centipedes, myrrh, cassia twigs, angelica sinensis, black kidney beans, cortex eucommiae, radix saposhnikoviae, radix astragali, radix paeoniae alba, radix liquiritiae, white mustard seeds and radix achyranthis bidentatae. The invention further provides a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition has the advantages that when the traditional Chinese medicine composition is applied to treatment of rheumatism pathogenic factors remaining in the body and various kinds of arthralgia of vein, jointsand muscles, the effective rate reaches 90% or above, and the cure rate is 96% or above; patients with the slight disease can be cured within 10-20 days; the patients with the severe diseases of the large and small swelled joints, upper and lower limb paralysis, osteonecrosis, rheumatoid arthritis, gout and rheumatic heart disease can be cured after taking the medicine for 3-4 treatment courses; but for complete cure of rheumatoid factors caused by long-term use of hormones, wrong treatment and delayed treatment, residues still exist in short time.
Owner:宿迁春铭健康管理咨询有限公司
Multi-target bone rehabilitation physical therapy patch based on yin-yang balance compatibility and magnetoelectric infiltration promotion and preparation method of multi-target bone rehabilitation physical therapy patch
PendingCN121754631AHeavy metal active ingredientsAnthropod material medical ingredientsArthritisLumbar
The invention provides a multi-target bone rehabilitation physiotherapy patch based on yin-yang balance compatibility and magnetoelectric infiltration promotion and a preparation method of the multi-target bone rehabilitation physiotherapy patch. The bone rehabilitation physiotherapy patch integrates a traditional Chinese medicine yin-yang balance compatibility theory and a modern magnetoelectric infiltration promotion technology; the obtained rehabilitation physical therapy patch is suitable for prevention, control and rehabilitation treatment of bone diseases such as neck, shoulder and lumbar vertebra pain, arthritis, osteonecrosis and fracture later rehabilitation as well as chronic diseases related to bone injuries.
Owner:临沂经济开发区李易罡健康信息咨询经营部
Bone necrosis repair stent with osteoblast implantation function
Bone necrosis repair stent with osteoblast implantation function, comprising a metal stent (1), wherein extension blocks (3) are rigidly connected to the outside of the metal stent (1), and the metal stents (1) are pivotally connected to telescopic rods (4) via the extension blocks (3), support blocks (6) are arranged on the metal stent (1), wherein damping pivot axes (12) are rigidly connected to the top of the support blocks (6), and the top of the support blocks (6) are rotatably connected to sleeves (7) via the damping pivot axes (12), wherein fluid outlet openings (11) are formed on the surface of the sleeves (7), and the inside of the sleeves (7) is in contact with inner tubes (5), wherein through holes (16) are provided on the outside of the inner tubes (5), and piston rods (9) are movably inserted through one end of the inner tubes (5), wherein at one end of the piston rods (9) a sealing plug (17) is firmly attached,wherein the edge of the sealing plug (17) is in contact with the inner wall of the inner tubes (5), push plates are firmly connected at the other end of the piston rods (9) and limiting components are arranged on the outside of the sleeves (7).
Owner:CHENGDU BAOHIP FEMORAL HEAD ORTHOPEDIC HOSPITAL CO LTD
Application of a traditional Chinese medicine composition in the preparation of medicines or health products for treating osteoporosis and osteonecrosis
ActiveCN105055863BGood curative effectLittle side effectsInanimate material medical ingredientsSkeletal disorderBone densityTherapeutic effect
The invention discloses an application of a traditional Chinese medicine composition in the preparation of medicines or health care products for treating osteoporosis and osteonecrosis. The traditional Chinese medicine composition of the present invention is made of Polygonum multiflorum, Polygonatum, Rehmannia glutinosa, Gorgon fruit, Ziheche, black sesame, Astragalus, Poria cocos, Chinese yam, American ginseng, Radix asparagus, Ophiopogon japonicus, pearl, amber, keel, arborvitae leaves, black soybean to make. Pharmacodynamic experiments show that the Chinese medicine composition of the present invention can increase the bone density of osteoporosis model rats and serum calcium and phosphorus levels; it can increase the distribution of capillaries in the femoral head of rats with steroid-induced necrosis of the femoral head, and reduce the distribution of steroid-induced necrosis of the femoral head model. Fat deposits in the femoral head bone tissue of rats, and clinical research results also show that the traditional Chinese medicine composition of the present invention has a good therapeutic effect on osteoporosis and femoral head necrosis. The traditional Chinese medicine composition provided by the invention has the advantages of good curative effect and small side effects in treating osteoporosis and osteonecrosis, and has good clinical application prospect.
Owner:雷允上药业集团有限公司